| 1 |
<p align="left"><b>Development of NCE`s</b></p> |
| 2 |
<table width="90%" border="0" cellspacing="0" cellpadding="0" align="center"> |
| 3 |
<tr> |
| 4 |
<td height="10" width="19%"> |
| 5 |
<div align="center"><b>PROJECT</b></div> |
| 6 |
</td> |
| 7 |
<td height="10" width="26%"> |
| 8 |
<div align="center"><b>INDICATION</b></div> |
| 9 |
</td> |
| 10 |
<td height="10" width="24%"> |
| 11 |
<div align="center"><b>STATUS</b></div> |
| 12 |
</td> |
| 13 |
<td height="10" width="31%"> |
| 14 |
<div align="center"><b>MARKET POTENTIAL </b></div> |
| 15 |
</td> |
| 16 |
</tr> |
| 17 |
</table> |
| 18 |
<table width="90%" border="1" cellspacing="0" cellpadding="0" align="center"> |
| 19 |
<tr> |
| 20 |
<td width="19%"> |
| 21 |
<div align="center">PLD - 116</div> |
| 22 |
</td> |
| 23 |
<td width="26%"> |
| 24 |
<div align="center">Inflammatory Bowel Disease (IBD)</div> |
| 25 |
</td> |
| 26 |
<td width="24%"> |
| 27 |
<div align="center">Clinical Trials</div> |
| 28 |
</td> |
| 29 |
<td width="31%"> |
| 30 |
<div align="center">US$ 600 m. to US$ 1bn</div> |
| 31 |
</td> |
| 32 |
</tr> |
| 33 |
<tr> |
| 34 |
<td width="19%"> |
| 35 |
<div align="center">PLD - 117</div> |
| 36 |
</td> |
| 37 |
<td width="26%"> |
| 38 |
<div align="center">Oncology<br> |
| 39 |
Hematology</div> |
| 40 |
</td> |
| 41 |
<td width="24%"> |
| 42 |
<div align="center">Clinical Trials</div> |
| 43 |
</td> |
| 44 |
<td width="31%"> |
| 45 |
<div align="center">US$ 600-900 m.</div> |
| 46 |
</td> |
| 47 |
</tr> |
| 48 |
<tr> |
| 49 |
<td width="19%"> |
| 50 |
<div align="center">PLD - 118</div> |
| 51 |
</td> |
| 52 |
<td width="26%"> |
| 53 |
<div align="center">Anti-fungal</div> |
| 54 |
</td> |
| 55 |
<td width="24%"> |
| 56 |
<div align="center">Clinical Trials</div> |
| 57 |
</td> |
| 58 |
<td width="31%"> |
| 59 |
<div align="center">US$ 600-800 m.</div> |
| 60 |
</td> |
| 61 |
</tr> |
| 62 |
<tr> |
| 63 |
<td width="19%"> |
| 64 |
<div align="center">PLR - 1</div> |
| 65 |
</td> |
| 66 |
<td width="26%"> |
| 67 |
<div align="center">Anti-infective</div> |
| 68 |
</td> |
| 69 |
<td width="24%"> |
| 70 |
<div align="center">Discovery</div> |
| 71 |
</td> |
| 72 |
<td width="31%"> |
| 73 |
<div align="center">~ US$ 1 bn</div> |
| 74 |
</td> |
| 75 |
</tr> |
| 76 |
<tr> |
| 77 |
<td width="19%"> |
| 78 |
<div align="center">PLR - 13</div> |
| 79 |
</td> |
| 80 |
<td width="26%"> |
| 81 |
<div align="center">Inflammation<br> |
| 82 |
Asthma</div> |
| 83 |
</td> |
| 84 |
<td width="24%"> |
| 85 |
<div align="center">Discovery</div> |
| 86 |
</td> |
| 87 |
<td width="31%"> |
| 88 |
<div align="center">~ US$ 500 m.</div> |
| 89 |
</td> |
| 90 |
</tr> |
| 91 |
<tr> |
| 92 |
<td width="19%"> |
| 93 |
<div align="center">PLR - 9</div> |
| 94 |
</td> |
| 95 |
<td width="26%"> |
| 96 |
<div align="center">Anti-infective</div> |
| 97 |
</td> |
| 98 |
<td width="24%"> |
| 99 |
<div align="center">Discovery</div> |
| 100 |
</td> |
| 101 |
<td width="31%"> |
| 102 |
<div align="center">~ US$ 1 bn</div> |
| 103 |
</td> |
| 104 |
</tr> |
| 105 |
<tr> |
| 106 |
<td width="19%"> |
| 107 |
<div align="center">PLR - 14</div> |
| 108 |
</td> |
| 109 |
<td width="26%"> |
| 110 |
<div align="center">Inflammation<br> |
| 111 |
RA, IBD</div> |
| 112 |
</td> |
| 113 |
<td width="24%"> |
| 114 |
<div align="center">Discovery</div> |
| 115 |
</td> |
| 116 |
<td width="31%"> |
| 117 |
<div align="center">~ US$ 1 bn </div> |
| 118 |
</td> |
| 119 |
</tr> |
| 120 |
</table> |
| 121 |
<table width="100%" border="0" cellspacing="3" cellpadding="0"> |
| 122 |
<tr> |
| 123 |
<td> |
| 124 |
<hr size="1" width="100%"> |
| 125 |
</td> |
| 126 |
</tr> |
| 127 |
</table> |
| 128 |
<p><b>Development of Generics</b></p> |
| 129 |
<table width="90%" align="center" border="0" cellspacing="0" cellpadding="0"> |
| 130 |
<tr> |
| 131 |
<td width="25%" height="35"> |
| 132 |
<div align="center"><b>GENERIC PRODUCT</b></div> |
| 133 |
</td> |
| 134 |
<td width="23%" height="35"> |
| 135 |
<div align="center"><b>FIRST REGISTRATION EXPECTED</b> </div> |
| 136 |
</td> |
| 137 |
<td width="25%" height="35"> |
| 138 |
<div align="center"><b>GENERIC PRODUCT</b></div> |
| 139 |
</td> |
| 140 |
<td width="27%" height="35"> |
| 141 |
<div align="center"><b>FIRST REGISTRATION EXPECTED</b></div> |
| 142 |
</td> |
| 143 |
</tr> |
| 144 |
<tr> |
| 145 |
<td colspan="4"> |
| 146 |
<table width="100%" border="1" cellspacing="0" cellpadding="0"> |
| 147 |
<tr> |
| 148 |
<td width="25%">Simvastatin</td> |
| 149 |
<td width="23%"> |
| 150 |
<div align="center">2001</div> |
| 151 |
</td> |
| 152 |
<td width="25%">Losartan</td> |
| 153 |
<td width="27%"> |
| 154 |
<div align="center">2002</div> |
| 155 |
</td> |
| 156 |
</tr> |
| 157 |
<tr> |
| 158 |
<td width="25%">Loratadin</td> |
| 159 |
<td width="23%"> |
| 160 |
<div align="center">2001</div> |
| 161 |
</td> |
| 162 |
<td width="25%">Carvedilol</td> |
| 163 |
<td width="27%"> |
| 164 |
<div align="center">2002</div> |
| 165 |
</td> |
| 166 |
</tr> |
| 167 |
<tr> |
| 168 |
<td width="25%">Erythropoietin</td> |
| 169 |
<td width="23%"> |
| 170 |
<div align="center">2001</div> |
| 171 |
</td> |
| 172 |
<td width="25%">Bisoprolol</td> |
| 173 |
<td width="27%"> |
| 174 |
<div align="center">2003</div> |
| 175 |
</td> |
| 176 |
</tr> |
| 177 |
<tr> |
| 178 |
<td width="25%">Warfarin</td> |
| 179 |
<td width="23%"> |
| 180 |
<div align="center">2001</div> |
| 181 |
</td> |
| 182 |
<td width="25%">Losartan+HCTZ</td> |
| 183 |
<td width="27%"> |
| 184 |
<div align="center">2003</div> |
| 185 |
</td> |
| 186 |
</tr> |
| 187 |
<tr> |
| 188 |
<td width="25%">Diklofenac</td> |
| 189 |
<td width="23%"> |
| 190 |
<div align="center">2001</div> |
| 191 |
</td> |
| 192 |
<td width="25%">Clarithromycin</td> |
| 193 |
<td width="27%"> |
| 194 |
<div align="center">2003</div> |
| 195 |
</td> |
| 196 |
</tr> |
| 197 |
<tr> |
| 198 |
<td width="25%">Ca folinat</td> |
| 199 |
<td width="23%"> |
| 200 |
<div align="center">2001</div> |
| 201 |
</td> |
| 202 |
<td width="25%">Venlafaxine</td> |
| 203 |
<td width="27%"> |
| 204 |
<div align="center">2003</div> |
| 205 |
</td> |
| 206 |
</tr> |
| 207 |
<tr> |
| 208 |
<td width="25%">Ondansetron</td> |
| 209 |
<td width="23%"> |
| 210 |
<div align="center">2002</div> |
| 211 |
</td> |
| 212 |
<td width="25%">Interferon alpha</td> |
| 213 |
<td width="27%"> |
| 214 |
<div align="center">2003</div> |
| 215 |
</td> |
| 216 |
</tr> |
| 217 |
<tr> |
| 218 |
<td width="25%">Torasemid</td> |
| 219 |
<td width="23%"> |
| 220 |
<div align="center">2002</div> |
| 221 |
</td> |
| 222 |
<td width="25%">Paroxetin</td> |
| 223 |
<td width="27%"> |
| 224 |
<div align="center">2003</div> |
| 225 |
</td> |
| 226 |
</tr> |
| 227 |
<tr> |
| 228 |
<td width="25%">Amlodipin</td> |
| 229 |
<td width="23%"> |
| 230 |
<div align="center">2002</div> |
| 231 |
</td> |
| 232 |
<td width="25%">HGH</td> |
| 233 |
<td width="27%"> |
| 234 |
<div align="center">2003</div> |
| 235 |
</td> |
| 236 |
</tr> |
| 237 |
<tr> |
| 238 |
<td width="25%">Risperidone</td> |
| 239 |
<td width="23%"> |
| 240 |
<div align="center">2002</div> |
| 241 |
</td> |
| 242 |
<td width="25%">Meloxicam</td> |
| 243 |
<td width="27%"> |
| 244 |
<div align="center">2003</div> |
| 245 |
</td> |
| 246 |
</tr> |
| 247 |
<tr> |
| 248 |
<td width="25%">Alendronate</td> |
| 249 |
<td width="23%"> |
| 250 |
<div align="center">2002</div> |
| 251 |
</td> |
| 252 |
<td width="25%">Interferon beta</td> |
| 253 |
<td width="27%"> |
| 254 |
<div align="center">2004</div> |
| 255 |
</td> |
| 256 |
</tr> |
| 257 |
<tr> |
| 258 |
<td width="25%">Ciprofloxacin</td> |
| 259 |
<td width="23%"> |
| 260 |
<div align="center">2002</div> |
| 261 |
</td> |
| 262 |
<td width="25%">Indapamide</td> |
| 263 |
<td width="27%"> |
| 264 |
<div align="center">2004</div> |
| 265 |
</td> |
| 266 |
</tr> |
| 267 |
<tr> |
| 268 |
<td width="25%">Mesalazin</td> |
| 269 |
<td width="23%"> |
| 270 |
<div align="center">2002</div> |
| 271 |
</td> |
| 272 |
<td width="25%">Cytostatics (9)</td> |
| 273 |
<td width="27%"> |
| 274 |
<div align="center">2001-2003</div> |
| 275 |
</td> |
| 276 |
</tr> |
| 277 |
<tr> |
| 278 |
<td width="25%">G-CSF </td> |
| 279 |
<td width="23%"> |
| 280 |
<div align="center">2002</div> |
| 281 |
</td> |
| 282 |
<td width="25%">OTC products (9)</td> |
| 283 |
<td width="27%"> |
| 284 |
<div align="center">2001-2003</div> |
| 285 |
</td> |
| 286 |
</tr> |
| 287 |
</table> |
| 288 |
</td> |
| 289 |
</tr> |
| 290 |
</table> |
Parent Directory
| 
Revision Log